Z-160

Z-160 is an investigational small molecule drug that acts as a potent and selective oral N-type calcium channel (Cav2.2) blocker. It was developed for the treatment of chronic neuropathic pain conditions, including postherpetic neuralgia and lumbosacral radiculopathy. The drug demonstrated efficacy in multiple animal models of neuropathic and inflammatory pain and showed good selectivity over L-type calcium channels. Despite being well tolerated in clinical trials, development was discontinued after Phase II studies failed to meet primary endpoints for efficacy[2][5]. The compound received orphan drug designation from the FDA for postherpetic neuralgia[5].

Other names

1-(4-Benzhydryl-piperazin-1-yl)-3,3-diphenylpropan-1-one1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenylpropanone